Loading clinical trials...
Loading clinical trials...
A phase I trial to evaluate the safety and tolerability of ALS-357 when administered for four weeks as a topical ointment, in escalating doses, to patients with cutaneous metastatic melanoma and to ev...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Advanced Life Sciences, Inc.
NCT06961357 · Melanoma
NCT07379138 · Melanoma
NCT06529822 · Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, and more
NCT04855435 · Advanced Solid Tumor, Uveal Melanoma, Metastatic, and more
NCT04771520 · Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, and more
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions